Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481548 | 0.81 | APLNR (0.33) | APLNR | |
| SCHEMBL18483580 | 0.79 | APLNR (0.35) | APLNR | |
| SCHEMBL16649641 | 0.79 | ADRB2 (0.41) | APLNRCYP1A2 | |
| SCHEMBL14846893 | 0.79 | ADRB2 (0.41) | APLNRCYP1A2 | |
| SCHEMBL25763724 | 0.77 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19NPC1RAB9A | |
| SCHEMBL19551110 | 0.75 | MAPT (0.38) | APLNRNPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL20189723 | 0.75 | APLNR (0.65) | APLNR | |
| SCHEMBL12363180 | 0.75 | MAPT (0.38) | APLNRNPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL10105660 | 0.74 | APLNR (0.58) | APLNRCYP1A2 | |
| SCHEMBL2757603 | 0.74 | APLNR (0.36) | APLNRNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4474958-A | 2-Alkyl-5-halopyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | claimed |
| EP-0097451-A1 | 2-Alkyl-5-pyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-01-04 | — | — | EP | claimed |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| EP-4031544-B1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR AND SULFOXIMINE CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3468967-B1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC (CA) | 2023-07-26 | — | — | EP | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-7501413-B2 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-20070249629-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE | 2007-10-25 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241801-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-4474958-A | 2-Alkyl-5-halopyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0097451-A1 | 2-Alkyl-5-pyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | APLNR 4629/4885CYP1A2 17/4885CYP2C9 35/4885 |
| US-20070249629-A1 | Viral Polymerase Inhibitors | RPP30, POLR2A, POLR1E | APLNR 3900/4885CYP1A2 2284/4885CYP2C9 693/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | APLNR 2727/4885CYP1A2 2431/4885CYP2C9 1179/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | APLNR 591/4885CYP1A2 1150/4885CYP2C9 1167/4885 |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | APLNR 3930/4885CYP1A2 214/4885CYP2C9 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.